0 265

Cited 0 times in

창상감염증 및 피부감염증에 대한 Cefpodoxime proxetil의 임상연구

DC Field Value Language
dc.contributor.author이광훈-
dc.date.accessioned2021-12-27T16:51:17Z-
dc.date.available2021-12-27T16:51:17Z-
dc.date.issued1995-11-
dc.identifier.issn0529-3804-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/186197-
dc.description.abstractPatients with wound infection and cutaneous bacterial infection were enrolled in a study of oral] administered ecfpodoxime proxetil : 20 patients with infection received cefpodoxime proxetil 100 to 200mg twice daily for 6-9 days. 17 of 20(85.0%) evaluable patients were clinically cured post--therapy, the remainder being classified as marked improvement and moderate improvement. The pathogen eradication rate at the end of therapy was 9 of 9(100%). There was no significant a drug related adverse reaction. Cefpodoxime proxetil appears to be useful and safe agent in the therapy of skin infections.-
dc.description.statementOfResponsibilityprohibition-
dc.languageKorean-
dc.publisher최신의학사-
dc.relation.isPartOfNewest Medical Journal(최신의학)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title창상감염증 및 피부감염증에 대한 Cefpodoxime proxetil의 임상연구-
dc.title.alternativeClinical Study of Cefpodoxime Proxetil in the Treatment of Wound Infection and of Cutaneous Bacterial Infection-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Dermatology (피부과학교실)-
dc.contributor.googleauthor신극선-
dc.contributor.googleauthor나동균-
dc.contributor.googleauthor이광훈-
dc.contributor.googleauthor이정복-
dc.contributor.localIdA02674-
dc.relation.journalcodeJ02373-
dc.contributor.alternativeNameLee, Kwang Hoon-
dc.contributor.affiliatedAuthor이광훈-
dc.citation.volume38-
dc.citation.number11-
dc.citation.startPage31-
dc.citation.endPage35-
dc.identifier.bibliographicCitationNewest Medical Journal (최신의학), Vol.38(11) : 31-35, 1995-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.